Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Fung

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Current Medical Research and Opinion|April 6, 2016
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitusMaria Alba, John Xie, Albert Fung, et al.
Medical Education|April 5, 2025
Virtual Reality: Game Changer in Complex Surgery EducationPrachikumari Patel, Remi Gao, Albert Fung, et al.
Postgraduate Medicine|January 8, 2014
Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitorLindsay E Nicolle, George Capuano, Albert Fung, et al.
Intractable & Rare Diseases Research|September 4, 2025
Literature analysis and implication of biologic therapy for children with non-systemic juvenile idiopathic arthritis in real-world settingsAlbert Fung, Xiaomeng Yue, Patricia R Wigle, et al.
Hearing Research|October 27, 2018
Response of the inner ear to lipopolysaccharide introduced directly into scala mediaDaniel John Brown, Ljiljana Sokolic, Albert Fung, et al.
Hospital Practice (1995)|May 18, 2013
Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trialBruce Bode, Kaj Stenlöf, Daniel Sullivan, et al.
Annals of Emergency Medicine|June 21, 2008
Beta-blockers are associated with reduced risk of myocardial infarction after cocaine useSze Chun Albert Fung, Yiu Cheung Chan, Fei Lung Lau
Postgraduate Medicine|June 12, 2014
Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study resultsKeith Usiskin, Irina Kline, Albert Fung, et al.
Intractable & Rare Diseases Research|December 8, 2021
Off-label medication use in rare pediatric diseases in the United StatesAlbert Fung, Xiaomeng Yue, Patricia R Wigle, et al.
Postgraduate Medicine|March 23, 2016
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeksLawrence Blonde, Kaj Stenlöf, Albert Fung, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Current Medical Research and Opinion|April 6, 2016
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitusMaria Alba, John Xie, Albert Fung, et al.
Medical Education|April 5, 2025
Virtual Reality: Game Changer in Complex Surgery EducationPrachikumari Patel, Remi Gao, Albert Fung, et al.
Postgraduate Medicine|January 8, 2014
Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitorLindsay E Nicolle, George Capuano, Albert Fung, et al.
Intractable & Rare Diseases Research|September 4, 2025
Literature analysis and implication of biologic therapy for children with non-systemic juvenile idiopathic arthritis in real-world settingsAlbert Fung, Xiaomeng Yue, Patricia R Wigle, et al.
Hearing Research|October 27, 2018
Response of the inner ear to lipopolysaccharide introduced directly into scala mediaDaniel John Brown, Ljiljana Sokolic, Albert Fung, et al.
Hospital Practice (1995)|May 18, 2013
Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trialBruce Bode, Kaj Stenlöf, Daniel Sullivan, et al.
Annals of Emergency Medicine|June 21, 2008
Beta-blockers are associated with reduced risk of myocardial infarction after cocaine useSze Chun Albert Fung, Yiu Cheung Chan, Fei Lung Lau
Postgraduate Medicine|June 12, 2014
Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study resultsKeith Usiskin, Irina Kline, Albert Fung, et al.
Intractable & Rare Diseases Research|December 8, 2021
Off-label medication use in rare pediatric diseases in the United StatesAlbert Fung, Xiaomeng Yue, Patricia R Wigle, et al.
Postgraduate Medicine|March 23, 2016
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeksLawrence Blonde, Kaj Stenlöf, Albert Fung, et al.
Pageof 3